Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zelluna ASAOSTO:ULTIO 30 Equity-to-Asset is 0.93 as of Jun. 2026, which is 2% above its 10-year median of 0.91. GuruFocus rates OSTO:ULTIO with a GF Score™ of 30/100. The stock has 2 warning signs investors should review. Among 1,415 Biotechnology companies, Zelluna ASA ranks better than 90.6% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Zelluna ASA's Total Stockholders Equity for the quarter that ended in Jun. 2026 was kr105.74 Mil. Zelluna ASA's Total Assets for the quarter that ended in Jun. 2026 was kr113.70 Mil.
The historical rank and industry rank for Zelluna ASA's Equity-to-Asset or its related term are showing as below:
OSTO:ULTIo'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.71 Med: 0.91 Max: 0.98
Current: 0.93
During the past 11 years, the highest Equity to Asset Ratio of Zelluna ASA was 0.98. The lowest was 0.71. And the median was 0.91.
OSTO:ULTIo's Equity-to-Asset is ranked better than 90.6% of 1415
companies
in the Biotechnology industry
Industry Median: 0.68
vs OSTO:ULTIo: 0.93
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Zelluna ASA Equity-to-Asset Related Terms
Zelluna ASA Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Zelluna ASA's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:ULTIO vs VRTX, REGN, RVMD: Equity-to-Asset Comparison
For the Biotechnology subindustry, Zelluna ASA's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zelluna ASA Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zelluna ASA's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Zelluna ASA's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Zelluna ASA's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zelluna ASA (OSTO:ULTIO) has a Equity-to-Asset of 0.93 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Zelluna ASA and its competitors. This is near median its historical median of 0.91. Over the past decade, Zelluna ASA's Equity-to-Asset has ranged from 0.71 to 0.98. According to the industry distribution chart, Zelluna ASA ranks #133 out of 1415 companies in the Biotechnology industry, placing it in the top 9.4%.
Is Zelluna ASA's Equity-to-Asset too high?
Zelluna ASA's current Equity-to-Asset of 0.93 is near median its 10-year median of 0.91. Over the past 10 years, this metric has ranged from a low of 0.71 to a high of 0.98. The Biotechnology industry median Equity-to-Asset is 0.68. Zelluna ASA's value of 0.93 is 36.8% above this industry median. Based on the distribution chart, Zelluna ASA ranks #133 out of 1415 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Zelluna ASA has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Zelluna ASA's Equity-to-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Zelluna ASA ranks #133 out of 1415 companies for Equity-to-Asset. This places Zelluna ASA in the top 9% of its industry — outperforming the majority of peers. The industry median Equity-to-Asset is 0.68. Zelluna ASA's value of 0.93 is 36.8% above this benchmark. Historically, Zelluna ASA's own Equity-to-Asset has ranged from 0.71 to 0.98 over the past decade. While the company's 10-year median is 0.91 vs. the industry median of 0.68, Zelluna ASA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,415 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zelluna ASA's current Equity-to-Asset of 0.93 is 36.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Zelluna ASA and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zelluna ASA's current Equity-to-Asset is 0.93, which is near median its own 10-year median of 0.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zelluna ASA stock overvalued right now?
Zelluna ASA (OSTO:ULTIO) has a current Equity-to-Asset of 0.93. The current Equity-to-Asset is 0.93, which is near median its 10-year median of 0.91 and 36.8% above the Biotechnology industry median of 0.68. Zelluna ASA's overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Zelluna ASA (OSTO:ULTIO), the current Equity-to-Asset is 0.93 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Zelluna ASA is a biotechnology company established to eliminate solid cancers by unleashing the powerful elements of the immune system through pioneering the development of T cell receptor (TCR) guided natural killer (NK) cell therapies (TCR-NK). Its TCR-NK products are composed of healthy donor-derived NK cells that are genetically engineered to express a tumour-specific TCR that enable the TCR-NK cells to identify and eliminate cancer cells in the body of the patient. Its programme ZI-MA4-1, the first MAGE-A4-targeting TCR-NK therapy for solid tumours with high unmet medical need. Its other programmes include ZI-KL1-1, and ZI-PR-1.
30GF Score
Get the complete analysis for OSTO:ULTIO
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:ULTIO has been successfully added to your 
